VEGFA and atrophic macular degeneration: Outcomes from CATT indicate that 1 in 4 patients on aggressive anti-VEGF therapy developed fibrosis within 24 months [124] with greater risk of geographic atrophy in nAMD patients 2 to 5 years after start of therapy [125] which again, could reflect the natural history of treated nAMD [141].